Compare Sana Biotechnology Inc (SANA) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Veritone Inc — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $947.48M), while Veritone Inc trades at $0.87 (market cap $85.83M). The key difference: Sana Biotechnology Inc is far larger — about 11× Veritone Inc's market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals.
| SANA | VERI | |
|---|---|---|
Market Cap | $947.48M | $85.83M |
Sector | Health | Technology |
52-Week High | $5.92 | $8.39 |
52-Week Low | $2.68 | $0.79 |
Enterprise Value | $860.73M | $121.22M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Veritone (VERI) trades at $0.9155, up 0.99% on the day, amid a bearish technical signal with mixed oscillators. The company reported Q2 2026 revenue of $24.3 million, up 20% sequentially, but continues to post significant losses, with a net income margin of -117.54% in 2025. Recent news highlights a securities class action investigation announced by Kaskela Law on August 20, 2026, adding legal overhangs to operational challenges.
The outlook remains challenged by persistent unprofitability and negative cash flow from operations, offset by a balanced analyst consensus of 46% buy and 46% hold ratings. Key risks include ongoing legal scrutiny, high operating costs, and the need to achieve sustainable profitability to support the stock's valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
